Echocardiogram for Breast Cancer

(POCEB Trial)

This trial explores whether a tailored approach to heart imaging can reduce unnecessary tests while still detecting early heart problems in women undergoing HER2-targeted therapy for breast cancer. Participants will either receive regular echocardiograms (heart ultrasounds) or have the frequency adjusted based on their risk of heart issues. Women with HER2-positive breast cancer, scheduled for about a year of HER2-targeted therapy, can consider joining, especially if they have not experienced serious heart problems before. As an unphased trial, this study offers participants the chance to contribute to innovative research that could enhance heart health monitoring for future patients.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that echocardiograms safely assess heart health in breast cancer patients. They use no radiation and have no known side effects. One study found that echocardiograms did not increase the risk of death or heart failure in patients with early breast cancer. Another study reported that a small number (4.8%) of patients experienced heart issues after using echocardiograms for monitoring. However, these issues might relate to the cancer treatment itself, not the echocardiogram. Overall, echocardiograms provide a safe and well-tolerated method for monitoring heart function during breast cancer treatment.¹²³⁴⁵

Researchers are excited about this trial because it explores the use of echocardiograms to tailor heart monitoring for breast cancer patients receiving trastuzumab. Unlike the standard approach, which involves regular echocardiograms every three months, this trial investigates a more personalized imaging schedule based on the patient's risk of heart failure. This could lead to fewer unnecessary procedures for low-risk patients and more targeted monitoring for those at intermediate risk, potentially improving patient care and resource efficiency.

Research has shown that echocardiograms are useful for checking heart health in patients receiving HER2-targeted therapy for breast cancer. In this trial, participants will be divided into two groups to assess the frequency of echocardiogram monitoring. The Standard-of-care Group will receive echocardiograms before cycles 1, 5, 9, and 13 of trastuzumab and another after completion. The Judicious-imaging Group will have echocardiograms based on their risk of heart failure, with low-risk participants receiving them every 6 months and intermediate-risk participants every 4 months. One study found that only 4.8% of patients had serious heart problems when monitored with echocardiograms, indicating that regular heart checks can catch issues early. Another study found that 87% of patients on HER2 therapies had heart screenings, highlighting their importance in treatment plans. Echocardiograms help ensure patients can safely continue their cancer treatments while monitoring their heart health.²⁶⁷⁸⁹